의료 영상 분야의 AI 시장 : 예측, 경쟁구도 및 보험 상환 주도의 수익화(2024-2035년)

Report Overview

This Marketstrat® Horizon report provides a global 2024A–2035E analysis of artificial intelligence in medical imaging, including market sizing, segment forecasts, reimbursement-driven monetization, competitive architecture, regulatory and evidence trends, and strategic implications for vendors, providers, and investors.

The Global AI in Medical Imaging Horizon: Forecasts, Competitive Architecture, and Reimbursement-Driven Monetization, 2024A–2035E is a comprehensive Marketstrat® / Markintel® Horizon report analyzing the global market for AI-attributable revenue across medical imaging. The report evaluates how artificial intelligence is being commercialized across CT, MRI, X-ray / digital radiography, mammography / DBT, ultrasound, nuclear imaging, and PET, and how AI value is shifting from stand-alone algorithms toward workflow integration, reimbursement maturity, enterprise deployment, cloud / pay-per-use economics, and recurring software models.

The report is built around a reconciled 2024A–2035E market model and covers the major commercial dimensions of medical imaging AI: modality, clinical area, clinical application, technology layer, revenue stream, end-user organization, geography, and reimbursement tier. The base-case forecast places the global AI medical imaging market at approximately $3.8B in 2024A and approximately $33.6B by 2035E, with growth shaped by reimbursement expansion, enterprise platform adoption, AI-enabled productivity, cloud deployment, and disease-specific quantitative analytics.

Unlike reports that focus primarily on regulatory clearance counts or vendor lists, this report emphasizes monetization. It explains why AI tools with similar technical or regulatory profiles may monetize differently depending on payer coverage, workflow integration, clinical evidence, procurement model, buyer type, and enterprise deployment path. It also introduces a reimbursement-tier framework that separates mature reimbursed AI, developing reimbursement categories, non-reimbursed productivity AI, and hardware-embedded / out-of-tier AI.

The report includes detailed analysis of competitive positioning across imaging OEMs, enterprise imaging / PACS platforms, AI-native clinical platforms, reimbursed quantitative analytics specialists, breast and oncology AI vendors, reconstruction and acquisition AI vendors, generative reporting and workflow automation companies, orchestration and governance platforms, cloud infrastructure providers, and provider-network AI platforms.

Key areas covered

• Global AI medical imaging market forecast, 2024A–2035E
• TAM / SAM / expected market framing
• Market sizing by region, modality, clinical area, clinical application, revenue stream, technology layer, end-user organization, and reimbursement tier
• Base, bull, bear, and sensitivity scenarios
• Reimbursement-driven monetization and payment policy implications
• FDA, De Novo, Breakthrough Device, PCCP, EU AI Act / MDR, NMPA, PMDA / NHI, and other regulatory considerations
• Cardiac CT AI reimbursement and quantitative analytics
• Mammography and screening AI evidence pathways
• Enterprise imaging, PACS, reporting, orchestration, and AI governance
• Foundation-model and multi-condition AI strategy
• Cloud / pay-per-use and enterprise software monetization
• Provider-owned AI networks, teleradiology, and outpatient imaging economics
• Competitive landscape and M&A / partnership implications
• Strategic execution playbooks by stakeholder type

Market segmentation

• By modality: CT AI; MRI AI; X-ray / DR / mammography AI; ultrasound AI; nuclear / PET AI.
• By clinical area: oncology, cardiology, neurology, respiratory / pulmonary, orthopedics / MSK, multispecialty AI.
• By application: detection and diagnosis; workflow and orchestration; image reconstruction and acquisition; quantification and analytics; reporting and communication.
• By revenue stream: hardware-embedded AI; installed / enterprise software; professional / managed services; cloud / pay-per-use.
• By technology layer: deep learning, computer vision, traditional ML / radiomics, NLP / generative AI, robotics / automation, expert systems, foundation-model / multimodal AI.
• By end user: hospitals / IDNs, imaging centers / radiology groups, teleradiology providers, clinics / specialist offices, government / mobile / military / NGO.
• By geography: North America, Europe, APAC, Latin America, Middle East and Africa, with major country coverage.

Competitive landscape

The report analyzes the competitive landscape across the major AI imaging control points, including imaging OEMs, enterprise imaging vendors, PACS / RIS / VNA platforms, AI-native clinical platforms, reimbursed quantitative analytics companies, breast and oncology AI vendors, reconstruction and acquisition AI companies, reporting and workflow automation vendors, AI orchestration / governance platforms, cloud infrastructure providers, and provider-network AI platforms.

Companies discussed include GE HealthCare, Siemens Healthineers, Philips, Canon Medical, Fujifilm, United Imaging, Pro Medicus, Sectra, Intelerad, AGFA HealthCare, Aidoc, Viz.ai, RapidAI, Qure.ai, Annalise.ai, DeepHealth / RadNet, HeartFlow, Cleerly, Elucid, Circle Cardiovascular Imaging, Lunit, iCAD, ScreenPoint, Hologic, Vara, Rad AI, Microsoft / Nuance, deepc, CARPL.ai, Ferrum Health, Blackford, Incepto, AWS, Microsoft Azure, Google Cloud, NVIDIA, and others.

Why purchase this report

This report helps users:

• evaluate the size and structure of the global medical imaging AI market
• identify which AI imaging categories have the strongest monetization potential
• understand how reimbursement affects adoption, pricing, and defensibility
• compare opportunity across modalities, clinical areas, and technology layers
• benchmark competitive positioning across OEMs, PACS vendors, AI platforms, provider networks, and cloud infrastructure providers
• assess M&A, partnership, and market-entry opportunities
• support strategy, corporate development, investment, product planning, and GTM decisions

Report details

• Publisher: Marketstrat®
• Series: Markintel® Horizon Report
• Publication: June 2026
• Report ID: MINTH-D01101-26A
• Forecast period: 2024A–2035E
• Length: 300+ pages
• Tables / figures: 140+ tables and 70+ figures / frameworks
• Geographic coverage: Global, North America, Europe, APAC, LATAM, MEA, and major country markets

Table of Contents

SECTION 1 - EXECUTIVE SUMMARY

• 1.1 EXECUTIVE TAKEAWAYS
• 1.2 GLOBAL MARKET AT-A-GLANCE - BASE CASE
• 1.3 WHAT IS STRUCTURALLY CHANGING
• 1.4 THE AI MONETIZATION LAYER: WHERE VALUE IS MOVING
• 1.5 COMPETITIVE SIGNAL DASHBOARD
• 1.6 STRATEGIC IMPLICATIONS BY STAKEHOLDER
• 1.7 MARKETSTRAT VIEW: WINNERS AND VULNERABLE SEGMENTS
• 1.8 SIGNALS TO WATCH OVER THE NEXT 12–24 MONTHS
• 1.9 EXECUTIVE CONCLUSION

SECTION 2 - RESEARCH & METHODOLOGY

• 2.1 WHAT THIS REPORT IS - AND WHAT IT IS NOT
• 2.2 RESEARCH FOUNDATION AND EVIDENCE BASE
• 2.3 METHODOLOGY ARCHITECTURE
• 2.4 MARKET DEFINITION
• 2.5 SEGMENTATION SCHEMA
• 2.6 GEOGRAPHIC METHODOLOGY
• 2.7 CORE MARKET SIZING AND FORECASTING METHODOLOGY
• 2.8 REVENUE STREAM AND AI MONETIZATION METHODOLOGY
• 2.9 REIMBURSEMENT TIER METHODOLOGY
• 2.10 MARKET STRUCTURE VIEWS
• 2.11 COMPETITIVE LANDSCAPE METHODOLOGY
• 2.12 STRATEGIC FRAMEWORK METHODOLOGY
• 2.13 QUALITY CONTROL, RECONCILIATION, AND REPRODUCIBILITY
• 2.14 LIMITATIONS AND GUIDANCE FOR INTERPRETATION

SECTION 3 - STRATEGIC FRAMEWORKS & MARKET STRUCTURE

• 3.1 EXECUTIVE TAKEAWAYS
• 3.2 WORLD MARKET OVERVIEW
• 3.3 MARKET STRUCTURE - WHAT IS STRUCTURALLY CHANGING
• 3.4 MARKET STRUCTURE VIEWS
• 3.5 STRATEGIC FRAMEWORKS ARCHITECTURE
• 3.6 M³ MARKET MOMENTUM VIEW
• 3.7 TECHNOLOGY MATURITY VIEW
• 3.8 AI REVENUE BY STREAM - BRIDGE VIEW
• 3.9 REIMBURSEMENT TIER MARKET STRUCTURE
• 3.10 T-DIC - TECHNOLOGY DIFFUSION & IMPACT CURVE
• 3.11 SOLUTION ADOPTION & GROWTH
• 3.12 AI USE-CASE MONETIZATION ARCHITECTURE
• 3.13 GTM GROWTH–MATURITY MATRIX
• 3.14 ECOSYSTEM COLLABORATION
• 3.15 CONTROL PLANE MAP
• 3.16 PARTNERING DECISION TREE
• 3.17 ARC COMMERCIAL READINESS
• 3.18 UPGRADE & PACKAGE LADDER
• 3.19 AI REVENUE BRIDGE - 2024A TO 2035E
• 3.20 STRATEGIC IMPLICATIONS BY STAKEHOLDER TYPE
• 3.21 SIGNALS TO WATCH
• 3.22 BOTTOM LINE

SECTION 4 - COMPETITIVE LANDSCAPE & COMPANY SPOTLIGHTS

• 4.1 EXECUTIVE TAKEAWAYS
• 4.2 COMPETITIVE LANDSCAPE MAP
• 4.3 CROSS-CUTTING COMPETITIVE THESIS
• 4.4 COMPETITIVE POSITIONING FRAMEWORK
• 4.5 CLUSTER 1 - IMAGING OEM PLATFORM INCUMBENTS
• 4.6 CLUSTER 2 - ENTERPRISE IMAGING, PACS, VIEWER, AND WORKFLOW PLATFORMS
• 4.7 CLUSTER 3 - AI-NATIVE CLINICAL PLATFORMS
• 4.8 CLUSTER 4 - REIMBURSED AND QUANTITATIVE SPECIALTY ANALYTICS
• 4.9 CLUSTER 5 - BREAST, ONCOLOGY, AND SCREENING AI
• 4.10 CLUSTER 6 - RECONSTRUCTION, ACQUISITION, AND SCANNER PRODUCTIVITY AI
• 4.11 CLUSTER 7 - GENERATIVE REPORTING, FOLLOW-UP, AND WORKFLOW AUTOMATION
• 4.12 CLUSTER 8 - ORCHESTRATION, MARKETPLACE, CLOUD, AND GOVERNANCE
• 4.13 CLUSTER 9 - PROVIDER-NETWORK AI PLATFORMS AND TELERADIOLOGY
• 4.14 CLUSTER 10 - CHINA AND APAC CHAMPIONS
• 4.15 COMPANY SPOTLIGHTS - STRATEGIC LEADERS
• 4.16 COMPETITIVE WINNERS AND PRESSURE POINTS
• 4.17 M&A AND PARTNERSHIP OUTLOOK
• 4.18 STRATEGIC IMPLICATIONS BY STAKEHOLDER
• 4.19 SIGNALS TO WATCH
• 4.20 COMPETITIVE SIGNALS TIMELINE
• 4.21 BOTTOM LINE

SECTION 5 - MARKET ANALYSIS BY REGION / COUNTRY

• 5.1 EXECUTIVE TAKEAWAYS
• 5.2 GLOBAL REGIONAL FORECAST OVERVIEW
• 5.3 REGIONAL COMMERCIAL ARCHETYPES
• 5.4 NORTH AMERICA
• 5.5 UNITED STATES
• 5.6 CANADA
• 5.7 EUROPE
• 5.8 GERMANY
• 5.9 FRANCE
• 5.10 UNITED KINGDOM
• 5.11 ITALY
• 5.12 REST OF EUROPE
• 5.13 APAC
• 5.14 CHINA
• 5.15 JAPAN
• 5.16 INDIA
• 5.17 REST OF APAC
• 5.18 LATAM
• 5.19 MEA
• 5.20 COUNTRY-LEVEL OPPORTUNITY SCORECARD
• 5.21 REGIONAL GTM PLAYBOOKS
• 5.22 REGIONAL SIGNALS TO WATCH
• 5.23 STRATEGIC IMPLICATIONS BY STAKEHOLDER
• 5.24 REGIONAL GTM MOTION

SECTION 6 - MARKET ANALYSIS BY IMAGING MODALITY

• 6.1 EXECUTIVE TAKEAWAYS
• 6.2 GLOBAL FORECAST BY IMAGING MODALITY
• 6.3 MODALITY COMMERCIAL ARCHETYPES
• 6.4 CT AI
• 6.5 MRI AI
• 6.6 X-RAY / DR / MAMMOGRAPHY AI
• 6.7 ULTRASOUND AI
• 6.8 NUCLEAR / PET AI
• 6.9 CROSS-MODALITY COMPETITIVE DYNAMICS
• 6.10 MODALITY PRIORITY MATRIX
• 6.11 MODALITY-SPECIFIC GTM PLAYBOOKS
• 6.12 SIGNALS TO WATCH BY MODALITY
• 6.13 STRATEGIC IMPLICATIONS BY STAKEHOLDER
• 6.14 BOTTOM LINE

SECTION 7 - MARKET ANALYSIS BY CLINICAL AREA

• 7.1 EXECUTIVE TAKEAWAYS
• 7.2 GLOBAL FORECAST BY CLINICAL AREA
• 7.3 CLINICAL-AREA COMMERCIAL ARCHETYPES
• 7.4 ONCOLOGY IMAGING AI
• 7.5 CARDIOLOGY IMAGING AI
• 7.6 NEUROLOGY IMAGING AI
• 7.7 RESPIRATORY / PULMONARY IMAGING AI
• 7.8 ORTHOPEDICS / MSK IMAGING AI
• 7.9 OTHER / MULTISPECIALTY IMAGING AI
• 7.10 CLINICAL AREA X MODALITY CROSSWALK
• 7.11 CLINICAL-AREA PRIORITY MATRIX
• 7.12 COMPETITIVE DYNAMICS BY CLINICAL AREA
• 7.13 SIGNALS TO WATCH BY CLINICAL AREA
• 7.14 STRATEGIC IMPLICATIONS BY STAKEHOLDER
• 7.15 BOTTOM LINE

SECTION 8 - MARKET ANALYSIS BY REVENUE STREAM AND MONETIZATION MODEL

• 8.1 EXECUTIVE TAKEAWAYS
• 8.2 GLOBAL FORECAST BY REVENUE STREAM
• 8.3 REVENUE STREAM DEFINITIONS
• 8.4 HARDWARE-EMBEDDED AI
• 8.5 INSTALLED / ENTERPRISE SOFTWARE
• 8.6 PROFESSIONAL / MANAGED SERVICES
• 8.7 CLOUD / PAY-PER-USE
• 8.8 PRICING AND PACKAGING ARCHETYPES
• 8.9 REVENUE STREAM BY REGION
• 8.10 REVENUE STREAM X CLINICAL AREA CROSSWALK
• 8.11 COMPETITIVE DYNAMICS BY REVENUE STREAM
• 8.12 SIGNALS TO WATCH, 2026–2030
• 8.13 STRATEGIC IMPLICATIONS BY STAKEHOLDER TYPE
• 8.14 BOTTOM LINE

SECTION 9 - MARKET ANALYSIS BY CLINICAL APPLICATION / USE CASE

• 9.1 EXECUTIVE TAKEAWAYS
• 9.2 GLOBAL FORECAST BY CLINICAL APPLICATION
• 9.3 CLINICAL APPLICATION DEFINITIONS
• 9.4 DETECTION & DIAGNOSIS
• 9.5 QUANTIFICATION & ANALYTICS
• 9.6 WORKFLOW & ORCHESTRATION
• 9.7 REPORTING & COMMUNICATION
• 9.8 IMAGE RECONSTRUCTION & ACQUISITION
• 9.9 CLINICAL APPLICATION X MODALITY CROSSWALK
• 9.10 CLINICAL APPLICATION X CLINICAL AREA CROSSWALK
• 9.11 REGIONAL MONETIZATION LOGIC BY APPLICATION
• 9.12 COMPETITIVE DYNAMICS BY APPLICATION
• 9.13 SIGNALS TO WATCH, 2026–2030
• 9.14 STRATEGIC IMPLICATIONS BY STAKEHOLDER
• 9.15 BOTTOM LINE

SECTION 10 - MARKET ANALYSIS BY END-USE ORGANIZATION / BUYER TYPE

• 10.1 EXECUTIVE TAKEAWAYS
• 10.2 GLOBAL FORECAST BY END-USE ORGANIZATION
• 10.3 END-USE ORGANIZATION DEFINITIONS
• 10.4 HOSPITALS / IDNS
• 10.5 IMAGING CENTERS / RADIOLOGY GROUPS
• 10.6 TELERADIOLOGY PROVIDERS
• 10.7 CLINICS / SPECIALIST OFFICES
• 10.8 OTHER / GOVERNMENT, MOBILE, MILITARY, NGO
• 10.9 END-USE ORGANIZATION X REVENUE MODEL CROSSWALK
• 10.10 END-USE ORGANIZATION X CLINICAL APPLICATION CROSSWALK
• 10.11 REGIONAL READOUT BY BUYER TYPE
• 10.12 COMPETITIVE DYNAMICS BY BUYER TYPE
• 10.13 SIGNALS TO WATCH, 2026–2030
• 10.14 STRATEGIC IMPLICATIONS BY STAKEHOLDER
• 10.15 BOTTOM LINE

SECTION 11 - MARKET ANALYSIS BY AI TECHNOLOGY / MODEL ARCHITECTURE

• 11.1 EXECUTIVE TAKEAWAYS
• 11.2 GLOBAL FORECAST BY AI TECHNOLOGY
• 11.3 TECHNOLOGY DEFINITIONS
• 11.4 DEEP LEARNING / CNNS / TRANSFORMER-ENHANCED IMAGING MODELS
• 11.5 CLASSICAL COMPUTER VISION
• 11.6 TRADITIONAL MACHINE LEARNING / RADIOMICS
• 11.7 NLP / GENAI / REPORTING AI
• 11.8 ROBOTICS / AUTOMATION / IMAGE-GUIDED AI
• 11.9 EXPERT SYSTEMS / RULE ENGINES
• 11.10 FOUNDATION MODELS / MULTIMODAL AI OVERLAY
• 11.11 TECHNOLOGY X APPLICATION CROSSWALK
• 11.12 REGIONAL TECHNOLOGY READOUT
• 11.13 COMPETITIVE DYNAMICS BY TECHNOLOGY LAYER
• 11.14 SIGNALS TO WATCH, 2026–2030
• 11.15 STRATEGIC IMPLICATIONS BY STAKEHOLDER
• 11.16 BOTTOM LINE

SECTION 12 - MARKET ANALYSIS BY REIMBURSEMENT TIER / PAYMENT MATURITY

• 12.1 EXECUTIVE TAKEAWAYS
• 12.2 GLOBAL FORECAST BY REIMBURSEMENT TIER
• 12.3 REIMBURSEMENT TIER DEFINITIONS
• 12.4 TIER 1 - MATURE REIMBURSEMENT
• 12.5 TIER 2 - DEVELOPING REIMBURSEMENT
• 12.6 TIER 3 - NO AI-SPECIFIC REIMBURSEMENT
• 12.7 HARDWARE-EMBEDDED / OUT-OF-TIER AI
• 12.8 REGIONAL REIMBURSEMENT READOUT
• 12.9 REIMBURSEMENT TIER X APPLICATION CROSSWALK
• 12.10 VENDOR IMPLICATIONS BY REIMBURSEMENT TIER
• 12.11 REIMBURSEMENT SIGNALS TO WATCH, 2026–2030
• 12.12 SCENARIO IMPLICATIONS
• 12.13 STRATEGIC IMPLICATIONS BY STAKEHOLDER
• 12.14 BOTTOM LINE

SECTION 13 - COMPETITIVE ARCHITECTURE & STRATEGIC POSITIONING

• 13.1 COMPETITIVE ARCHITECTURE THESIS: THE MARKET IS MOVING FROM ALGORITHM OWNERSHIP TO WORKFLOW CONTROL
• 13.2 COMPETITIVE ARCHITECTURE: SEVEN POWER CENTERS ARE EMERGING
• 13.3 HOW COMPETITION WORKS: THE MOAT HAS MOVED UP THE STACK
• 13.4 OEM PLATFORM INCUMBENTS: SCANNER CONTROL IS STILL POWERFUL, BUT NOT SUFFICIENT
• 13.5 AI-NATIVE PLATFORMS AND FOUNDATION MODELS: THE PLATFORM THESIS HAS REAL MOMENTUM
• 13.6 REPORTING, DOCUMENTATION, AND GENAI: THE REPORT IS BECOMING THE NEXT CONTROL PLANE
• 13.7 POINT-SOLUTION AI: CLEARANCE IS NO LONGER ENOUGH
• 13.8 REIMBURSED SPECIALIST LAYER: CLINICAL UTILITY BEATS BREADTH
• 13.9 ENTERPRISE IMAGING PLATFORMS: THE VIEWER IS BECOMING THE AI DISTRIBUTION CHANNEL
• 13.10 NEUTRAL MARKETPLACES AND AI AGGREGATORS: USEFUL LAYER, FRAGILE ECONOMICS
• 13.11 HYPERSCALERS AND INFRASTRUCTURE: ENABLERS, NOT YET PRIMARY CLINICAL WINNERS
• 13.12 PROVIDER-PLATFORM HYBRIDS: BUYERS ARE BECOMING VENDORS
• 13.13 REGIONAL VENDOR ECOSYSTEMS
• 13.14 COMPETITIVE WINNERS, WATCHLIST, AND AT-RISK SEGMENTS
• 13.15 M&A AND PARTNERSHIP IMPLICATIONS
• 13.16 STRATEGIC IMPLICATIONS BY AUDIENCE
• 13.17 SECTION 13 BOTTOM LINE

SECTION 14 - COMMERCIALIZATION, PRICING & REIMBURSEMENT ARCHITECTURE

• 14.1 COMMERCIALIZATION THESIS: AI IMAGING IS MOVING FROM FEATURE MONETIZATION TO ECONOMIC CAPTURE
• 14.2 THE REIMBURSEMENT TIER FRAMEWORK: THE MOST IMPORTANT COMMERCIAL SEGMENTATION
• 14.3 CARDIAC CT AI IS THE COMMERCIAL BENCHMARK
• 14.4 PRICING MODELS: FIVE COMMERCIAL ARCHETYPES ARE EMERGING
• 14.5 PACKAGING LADDER: AI MUST MOVE FROM MODULES TO OPERATING-LAYER ECONOMICS
• 14.6 BUYER-SPECIFIC MONETIZATION: THE SAME AI PRODUCT NEEDS DIFFERENT COMMERCIAL MOTIONS
• 14.7 REIMBURSEMENT PATHWAYS: DETECTION ALONE RARELY WINS
• 14.8 DIRECT-TO-CONSUMER AND PATIENT-PAID AI: USEFUL BUT NOT UNIVERSAL
• 14.9 CLOUD / PAY-PER-USE: THE LONG-TERM MARGIN POOL
• 14.10 OEM COMMERCIAL STRATEGY: EMBED HYGIENE AI, MONETIZE OUTCOMES AI
• 14.11 PLATFORM VENDOR STRATEGY: WIN THE INTEGRATION BUDGET, NOT JUST THE ALGORITHM BUDGET
• 14.12 REGIONAL MONETIZATION MODELS: ONE GLOBAL PRICING STRATEGY FAILS
• 14.13 COMMERCIALIZATION BY USE CASE: WHAT GETS PAID, WHAT GETS BUNDLED, WHAT GETS BURIED
• 14.14 CONTRACTING GUARDRAILS: WHAT VENDORS SHOULD NOT DO
• 14.15 COMMERCIAL KPIS: THE METRICS THAT DETERMINE RENEWAL
• 14.16 SECTION TAKEAWAYS

SECTION 15 - REGULATORY, EVIDENCE & GOVERNANCE ROADMAP

• 15.1 SECTION THESIS: CLEARANCE IS NO LONGER THE FINISH LINE
• 15.2 GLOBAL REGULATORY ARCHITECTURE: FOUR DISTINCT MARKETS, NOT ONE
• 15.3 U.S. REGULATORY AND COVERAGE PATHWAY: FDA CLEARANCE IS NECESSARY BUT NOT SUFFICIENT
• 15.4 FDA AND CHANGE CONTROL: PCCP BECOMES A STRATEGIC ADVANTAGE
• 15.5 EUROPE: MDR + AI ACT TURNS COMPLIANCE INTO A COMPETITIVE MOAT
• 15.6 EU SIMPLIFICATION COULD HELP, BUT NOT ENOUGH TO REMOVE THE COMPLIANCE TAX
• 15.7 CHINA: INDUSTRIAL POLICY, PROCUREMENT, AND DATA LOCALIZATION DEFINE THE MARKET
• 15.8 JAPAN: THE MOST ATTRACTIVE APPROVAL-TO-PAYMENT COUPLING OUTSIDE THE U.S.
• 15.9 EVIDENCE HIERARCHY: THE BAR IS MOVING FROM AUC TO OUTCOMES
• 15.10 MAMMOGRAPHY AI IS THE EVIDENCE BENCHMARK
• 15.11 CT AI AND FOUNDATION MODELS: EVIDENCE IS LAGGING COMMERCIAL EXCITEMENT
• 15.12 POST-MARKET SURVEILLANCE: THE NEXT GOVERNANCE BATTLEGROUND
• 15.13 CYBERSECURITY AND PLATFORM RELIABILITY ARE NOW COMMERCIAL ISSUES
• 15.14 LIABILITY AND HUMAN OVERSIGHT: AUTONOMOUS AI REMAINS CONSTRAINED
• 15.15 REGULATORY FRICTION FAVORS INCUMBENTS BUT DOES NOT GUARANTEE PLATFORM SUCCESS
• 15.16 REGULATORY AND EVIDENCE SCORECARD BY USE CASE
• 15.17 ENTERPRISE AI GOVERNANCE BLUEPRINT
• 15.18 REGULATORY WATCHLIST: 2026–2030
• 15.19 STRATEGIC RECOMMENDATIONS
• 15.20 SECTION TAKEAWAYS

SECTION 16 - SCENARIO OUTLOOK, FORECAST SENSITIVITY & STRATEGIC PRIORITIES

• 16.1 SECTION THESIS: THE MARKET IS STILL HIGH-GROWTH, BUT THE EASY GROWTH ASSUMPTION IS GONE
• 16.2 UPDATED FORECAST ARCHITECTURE: TAM, SAM, AND EXPECTED MARKET
• 16.3 WHY THE GROWTH CURVE WAS REVISED
• 16.4 BASE, BULL, BEAR, AND TAIL RISK SCENARIOS
• 16.5 BASE CASE: WHAT MUST GO RIGHT
• 16.6 BULL CASE: WHAT CREATES THE UPSIDE
• 16.7 BEAR CASE: WHAT BREAKS THE FORECAST
• 16.8 SENSITIVITY RANKING: THE FIVE VARIABLES THAT MATTER MOST
• 16.9 REIMBURSEMENT TIER MIGRATION: THE CORE ECONOMIC RESET
• 16.10 REGIONAL FORECAST: ONE GLOBAL MARKET, FOUR COMMERCIAL CLOCKS
• 16.11 COUNTRY IMPLICATIONS: THE U.S. STILL LEADS MONETIZATION, BUT INDIA AND CHINA GAIN STRATEGIC WEIGHT264
• 16.12 MODALITY READOUT: CT ANCHORS REIMBURSEMENT; MRI BECOMES THE LARGEST 2035 POOL
• 16.13 FOUNDATION MODELS: THE LARGEST UPSIDE AND LARGEST DOWNSIDE DRIVER
• 16.14 PLATFORM CONTROL VS ALGORITHM DIFFERENTIATION
• 16.15 OEM ECONOMICS: SERVICE AND RECURRING REVENUE REMAIN THE MOAT
• 16.16 INVESTMENT IMPLICATIONS
• 16.17 FORECAST CHECKPOINT CALENDAR
• 16.18 STRATEGIC PRIORITIES BY STAKEHOLDER
• 16.19 SECTION TAKEAWAYS

SECTION 17 - STRATEGIC EXECUTION PLAYBOOK, COMMERCIALIZATION ROADMAP & BOARD-LEVEL ACTIONS

• 17.1 SECTION THESIS: THE MARKET HAS MOVED FROM FORECASTING TO EXECUTION
• 17.2 STRATEGIC PRIORITY STACK: WHAT MANAGEMENT TEAMS SHOULD DO FIRST
• 17.3 THE FOUR STRATEGIC RULES FOR AI IMAGING VENDORS
• 17.4 COMMERCIAL PLAYBOOK BY VENDOR ARCHETYPE
• 17.5 REIMBURSEMENT-LED GTM FRAMEWORK
• 17.6 PRODUCT ARCHITECTURE: BUILD FOR THE ENTERPRISE, NOT THE DEMO
• 17.7 PRICING AND CONTRACTING ARCHITECTURE
• 17.8 EVIDENCE STRATEGY: BUILD THE REIMBURSEMENT FILE BEFORE THE PAYER MEETING
• 17.9 REGIONAL EXECUTION PLAYBOOK
• 17.10 M&A AND PARTNERSHIP PLAYBOOK
• 17.11 PROVIDER IMPLEMENTATION BLUEPRINT
• 17.12 INVESTOR DILIGENCE SCORECARD
• 17.13 BOARD-LEVEL KPI DASHBOARD
• 17.14 2026–2030 WATCHLIST
• 17.15 NO-REGRET MOVES BY STAKEHOLDER
• 17.16 STRATEGIC SYNTHESIS: WHAT “WINNING” LOOKS LIKE BY
• 17.17 SECTION TAKEAWAYS

SECTION 18 - APPENDIX, WATCHLIST & KPI DASHBOARD

• 18.1 SECTION THESIS: THE MARKET NOW REQUIRES CONTINUOUS SIGNAL MONITORING
• 18.2 2026–2030 EXECUTIVE WATCHLIST
• 18.3 TOP 25 SIGNALS TO TRACK THROUGH
• 18.4 2026–2030 SIGNAL CALENDAR
• 18.5 BOARD-LEVEL KPI DASHBOARD
• 18.6 FORECAST REVISION TRIGGER RULES
• 18.7 METHODOLOGY NOTES
• 18.8 SEGMENTATION DEFINITIONS
• 18.9 METHODOLOGICAL GUARDRAILS FOR FORECAST INTERPRETATION
• 18.10 FORECAST RISK REGISTER
• 18.11 GREEN-FLAG / RED-FLAG SCORECARD
• 18.12 GLOSSARY
• 18.13 APPENDIX: CRITICAL ASSUMPTIONS REGISTER